Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China

Table 3 Patients treatment and outcomes

Patient no	Stage	Surgery	Further therapy	Response	Time to relapse (months)	Site of relapse	Overall survival (months)
1	I	Uni	CHOP+RT + IT	CR	38.77	skin, CNS	40.77
2	II	Bil	R-CHOP+CHOP	CR			116.47+
3	IV	Uni	No	PD			6.07
4	I	Bil	unknown	unknown	unknown	unknown	112.1+
5	unknown	Uni	unknown	unknown	unknown	unknown	89.97+
6	II	Uni	R-CHOP+CHOP	PR			3.4+
7	II	Uni	R-CHOP	CR			79.27
8	I	Uni	R-CHOP+RT + IT	CR	71.2	maxillary sinus	78.37+
9	I	Uni	unknown	unknown	unknown	unknown	77.53+
10	I	Uni	R-CHOP+IT	CR	54.23	CNS	76.63+
11	III	Uni	R-CHOP+IT	CR			71.8+
12	I	Uni	R-CHOP+RT + IT	CR			69.53+
13	III	Uni	R-CHOP+RT + IT	SD			28
14	I	Uni	No	CR			44.63+
15	IV	Uni	R-CHOP+IT	PD			3.1
16	I	Uni	No	CR			34.93+
17	I	Uni	unknown	unknown	unknown	unknown	34.17+
18	II	Uni	R-CHOP+RT + IT	CR			33.47+
19	I	Uni	No	CR	12.77	right neck	21.97
20	I	Uni	No	CR	8.6	soft tissue	16.2
21	I	Uni	RT	CR	2.6	right testis	53.63+
22	unknown	Biopsy	unknown	unknown	unknown	unknown	28.9+
23	I	Uni	R-CHOP	CR			11.8+
24	I	Uni	R-CHOP	CR			4.63+
25	II	Uni	unknown	unknown	unknown	unknown	93.23+
26	IV	Bil	No	PD			22.57
27	III	Bil	No	PD			35.27
28	IV	Biopsy	No	PD			12.17

Table 3 note: Uni Unilateral; Bil, Bilateral, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (rituximab Cyclophosphamide, doxorubicin, vincristine, prednisone), RT Radiotherapy, IT Intrathecal, CR Complete remission, SD Stable disease, PD Progressive disease, PR Partial remission, CNS Central nervous system.

ISSN: 1471-2407